• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MHRA Updates Guidance for NonCOVID-19 Clinical Trials

MHRA Updates Guidance for NonCOVID-19 Clinical Trials

February 22, 2021

Sponsors of nonCOVID-19 trials should assess how trial participants receiving COVID-19 vaccinations could impact their studies, according to updated guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

The agency also said protocols for new nonCOVID-19 trials should address whether or how to provide vaccinations to participants in order to avoid substantial protocol amendments in the future.

If a sponsor of an ongoing trial determines the vaccine would have no interaction with the drug being tested, they can inform the agency as part of their trials’ next substantial amendment, labeling it a “nonsubstantial update.”

But in cases where potential issues are identified — such as in trials testing immune-related mechanisms — a substantial amendment to the MHRA and the appropriate research ethics committee approval is required. In such cases, trial protocols must consider if a minimal period of time must separate dosing with the investigational product and administration of the vaccine. MHRA also requires a risk-benefit discussion to support sponsors’ decisions.

In blinded trials, MHRA said sponsors should consider whether their trial subjects would require unblinding in order to receive a COVID-19 vaccine. Although sponsors can unblind subjects on an individual basis, the agency said sponsors should encourage them to remain in the trial. “They should ideally not be withdrawn, unless they explicitly request this,” MHRA said.

Read the updated guidance here: http://bit.ly/3qEVDvp. MHRA said it is working on separate guidance for COVID-19 vaccine trials.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing